-
Amgen Partners with PostEra for Small-Molecule Drug Discovery Initiative
•
Biopharmaceutical company Amgen (NASDAQ: AMGN) has entered into a drug discovery collaboration with US-based PostEra, covering up to five small-molecule programs. As part of the agreement, Amgen will also secure a future option to leverage PostEra’s AI technology for its own pipeline development. Financial Details and PostEra’s Track RecordWhile the…
-
Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology
•
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with Guangdong Ruidio Technology Co., Ltd. Under the terms of the agreement, Baheal acquires commercialization rights to Ruidio’s series of radioactive drugs, including 99mTc-3PRGD2, 99mTc-HP-Ark2, and 99mTc-POFAP, as well as imaging equipment products such as SPECT.…
-
Pfizer and Astellas Pharma Secure FDA Approval for Xtandi in High-Risk Non-Metastatic Prostate Cancer
•
Partners Pfizer (NYSE: PFE) and Astellas Pharma (TSE: 4503) last week received indication extension approval from the US Food and Drug Administration (FDA) for their androgen receptor signaling inhibitor Xtandi (enzalutamide). The drug is now approved as a treatment for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high…
-
Yifan Pharmaceutical’s Subsidiary Receives FDA Approval for Ryzneuta (F-627)
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary, Evive Biotech Ltd., has received Biologic License Application (BLA) approval from the US Food and Drug Administration (FDA) for Ryzneuta (efbemalenograstim alfa, F-627). The drug is indicated to reduce the incidence of infection manifested as febrile neutropenia in…
-
AstraZeneca Receives FDA Approval for Truqap in HR-Positive, HER2-Negative Breast Cancer
•
UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced last week that it has received regulatory approval from the US Food and Drug Administration (FDA) for its first-in-class AKT inhibitor, Truqap (capivasertib), in combination with fulvestrant. This treatment is indicated for HR-positive, HER2-negative locally advanced or metastatic recurrent or refractory breast…
-
Alphamab Oncology’s JSKN003 ADC: Promising Preliminary Data in Advanced Solid Tumors
•
Alphamab Oncology (HKG: 9966) has released preliminary data from a Phase I clinical study on its JSKN003-KN026 antibody drug conjugate (ADC) in Australia, focusing on advanced solid tumors. This open-label, multi-center, dosage escalation study is designed to evaluate the safety, tolerability, and preliminary efficacy of the molecule in treating these…
-
Final Results of China’s Round 9 Volume-Based Procurement Tender Announced
•
The National Allied Procurement Office has released the finalized results and tender bid allocations for Round 9 of the national Volume-Based Procurement (VBP) tender program, which took place earlier this month. The total value of contracts awarded reached RMB 1.17 billion (USD 161.5 million), marking a 90% reduction from the…
-
BMS’s Augtyro Receives FDA Approval for ROS1-Positive NSCLC
•
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS, NYSE: BMY) registration approval for its next-generation tyrosine kinase inhibitor (TKI) Augtyro (repotrectinib) for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adults. This decision follows a priority review of Phase…
